Key Takeaways
- UNH climbed 8.16% during the past week, including a significant single-session gain
- The Centers for Medicare & Medicaid Services approved a 2.48% rate boost for Medicare Advantage in 2027
- Bernstein increased its price target to $411 while maintaining a Buy recommendation
- HSBC lifted its stance to Hold; Baird’s Michael Ha stands as the sole analyst with a Sell rating
- Despite the rally, UNH remains down approximately 7% in 2026 and more than 50% off its 2024 high
UnitedHealth Group (UNH) enjoyed its strongest weekly performance in over half a year, surging more than 8% following an unexpected Medicare Advantage reimbursement increase from federal regulators.
UnitedHealth Group Incorporated, UNH
The Centers for Medicare & Medicaid Services confirmed a 2.48% bump in Medicare Advantage payment rates for 2027. This represented a significant upgrade from the preliminary proposal that suggested rates would remain essentially unchanged.
The regulatory decision triggered a substantial single-day surge in the stock. Market participants had anticipated negative news, making the favorable rate adjustment a welcome surprise.
For more than ten years, Medicare Advantage has served as a critical revenue driver for UNH. However, escalating healthcare expenses combined with constrained government reimbursements had begun pressuring profitability, making this regulatory outcome particularly important.
Bernstein responded swiftly to the announcement. The investment firm boosted its UNH price objective to $411 while reaffirming its Buy recommendation.
According to Bernstein’s analysis, the CMS ruling transforms what might have been approximately a 4% drag on 2027 earnings into projected earnings expansion of about 1.4%. That represents a substantial turnaround.
HSBC analyst Sidharth Sahoo elevated UNH to Hold following the news. While not an outright bullish call, the upgrade reflects an improved risk-reward balance.
A Contrarian Voice
Not all analysts share the enthusiasm. Michael Ha at Baird maintained his Underperform rating, positioning him as the sole sell-side analyst among 31 firms tracking the stock.
Ha’s thesis suggests the payment bump may provide only temporary relief. He highlighted that fundamental challenges facing value-based care frameworks persist.
This perspective deserves consideration. The Medicare Advantage segment continues facing a complex operating landscape, despite the improved reimbursement backdrop.
Broader Context
UNH has forecasted declining revenues for 2026 — potentially its first annual revenue drop in more than 30 years. Membership numbers are anticipated to contract across commercial, Medicare, and Medicaid segments.
The stock continues trading roughly 7% lower year-to-date and remains over 50% beneath its 2024 record. While this week’s advance narrows those losses, considerable ground remains to be recovered.
Nevertheless, the analyst community maintains a generally positive stance. Among 31 analysts following UNH, 22 maintain Buy recommendations. The consensus 12-month price target suggests approximately 17% appreciation potential from present levels.
Optum, UNH’s diversified health services division encompassing pharmacy benefit management and care delivery operations, continues delivering earnings consistency while the traditional insurance operations encounter obstacles.
Market participants are now focused on Q1 2026 results. Medical cost trajectory and any revised Medicare Advantage profitability guidance will be the critical focus areas.
